LAMA3 and cancer: LINC00628 has been reported to inhibit the malignant progression of cancer through different mechanisms, such as binding to EZH2 to regulate the p57 or H3K27me3 level (76, 77), and interacting with the promoter of LAMA3 or VEGFA (78, 79).